Tpl2 is a key mediator of arsenite-induced signal transduction

Cancer Research

Volumn 69, Issue 20, 2009, Pages 8043-8049

  Kyung, Mi Lee ^a,b,c   Ki, Won Lee ^a,c   Bode, Ann M ^a   Hyong, Joo Lee ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Seoul National University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROSTAGLANDIN E2; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TUMOR PROGRESSION LOCUS 2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; EXPOSURE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

ANIMALS; ARSENITES; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 2; EPIDERMIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUCIFERASES; MAP KINASE KINASE KINASES; MICE; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TERATOGENS; TRANSCRIPTION FACTOR AP-1;

EID: 70350218781     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2316     Document Type: Article

References (32)

1. Cantor KP. Drinking water and cancer. Cancer Causes Control 1997;83:292-308.
2. Gebel TW. Arsenic and drinking water contamination. Science 1999;2835407:1458-1459
3. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol 1989;82:99-104.
4. Schwartz RA. Premalignant keratinocytic neoplasms. J Am Acad Dermatol 1996;352 Pt 1:223-242
5. Schwartz RA. Arsenic and the skin. Int J Dermatol 1997;364:241-250
6. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A 1993; 906:2251-2255 (Pubitemid 23078604)
7. Erny KM, Peli J, Lambert JF, Muller V, Diggelmann H. Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene 1996;139:2015-2020 (Pubitemid 26397462)
8. Ceci JD, Patriotis CP, Tsatsanis C, et al. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 1997;116:688-700. (Pubitemid 27157158)
9. Patriotis C, Makris A, Chernoff J, Tsichlis PN. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogenactivated protein kinase. Proc Natl Acad Sci U S A 1994; 9121:9755-9759 (Pubitemid 24311886)
10. Chiariello M, Marinissen MJ, Gutkind JS. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 2000;205: 1747-1758 (Pubitemid 30100193)
11. Belich MP, Salmeron A, Johnston LH, Ley SC. TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105. Nature 1999;3976717:363-368 (Pubitemid 29061651)
12. Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF-α induction by LPSis regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;1037: 1071-1083 (Pubitemid 32040907)
13. Sourvinos G, Tsatsanis C, Spandidos DA. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 1999;1835:4968-4973 (Pubitemid 29425303)
14. Ohara R, Hirota S, Onoue H, Nomura S, Kitamura Y, Toyoshima K. Identification of the cells expressing cot proto-oncogene mRNA. J Cell Sci 1995;108:97-103.
15. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;605:1306-1311
16. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;2010: 1939-1944 (Pubitemid 29476120)
17. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005;24:202-210 (Pubitemid 40812470)
18. Vanderveen EE, Grekin RC, Swanson NA, Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol 1986;1224: 407-412
19. Huang C, Li J, Ding M, et al. Arsenic-induced NFκB transactivation through ERKs- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001;2221-2:29-34. (Pubitemid 32910317)
20. Dong Z. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect 2002;110 Suppl 5:757-759
21. Hao CM, Yull F, Blackwell T, Komhoff M, Davis LS, Breyer MD. Dehydration activates an NF-κB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 2000;1068:973-982 (Pubitemid 30800855)
22. Choi HS, Kang BS, Shim JH, et al. Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J 2008;221:113-126
23. Ouyang W, Zhang D, Ma Q, Li J, Huang C. Cyclooxygenase- 2 induction by arsenite through the IKKβ/ NFκB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect 2007;1154: 513-518 (Pubitemid 46591103)
24. Pi J, Yamauchi H, Kumagai Y, et al. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 2002;1104:331-336 (Pubitemid 34308595)
25. 2 on protein tyrosine phosphatase activity in HER14 cells. Free Radic Biol Med 1994;163: 399-403.
26. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;14702: M69-78.
27. Jiang JG, Tang JB, Chen CL, et al. Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas. World J Gastroenterol 2004;1015:2168-2173 (Pubitemid 39144961)
28. Das S, Cho J, Lambertz I, et al. Tpl2/cot signals activate ERK, JNK, and NF-κB in a cell-type and stimulus-specific manner. J Biol Chem 2005;28025: 23748-23757 (Pubitemid 40884858)
29. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-κB activation by MAP kinase cascades. Immunobiology 1997;1981-3:35-49. (Pubitemid 28021380)
30. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;92:240-246
31. Chun KS, Kim SH, Song YS, Surh YJ. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 2004;255:713-722 (Pubitemid 38618522)
32. Huang C, Bode AM, Chen NY, et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 2001;211A:261-267